MET and non-small cell lung carcinoma: While onartuzumab and emibetuzumab fail to show significant efficacy in clinical trials [103,104], novel bispecific antibodies like amivantamab, which have higher MET affinity, have demonstrated efficacy in patients with EGFR exon 20 insertion mutated NSCLC by overcoming TKI resistance.